Latest Headlines

  1. Minaris Delivers 100% Manufacturing And Release Success For Chimeric Therapeutics' CDH17 Autologous CAR‑T Program 4/23/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, “Chimeric” or the “Company”), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.

  2. Andelyn Biosciences And ENCell Co., Ltd Announce Strategic Partnership To Expand Global Reach Of Gene Therapy Manufacturing 4/21/2026

    Andelyn Biosciences, ("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to accelerate the global delivery of life-changing gene therapies.

  3. One Brand Uniting Critical Fluid Management Components 4/17/2026

    CPC Biotech to make its public debut at INTERPHEX 2026, April 21–23, Javits Center, New York City.

  4. AST And Marchesini Group Debut Partnership Benefit With Expanded Drug Product Manufacturing Portfolio At INTERPHEX 2026 4/14/2026
  5. Grand River Aseptic Manufacturing Announces $100 Million Investment In Sterile Manufacturing Capabilities 4/14/2026

    Grand River Aseptic Manufacturing (“GRAM”), an Arlington Capital Partners portfolio company, is a leading provider of sterile fill-finish services. The company has announced a significant investment to expand its sterile injectable drug product manufacturing capacity and capabilities for high-volume commercial products.

  6. Andelyn Biosciences Partners With Evolyra Therapeutics For The Clinical Manufacturing Of Gene Therapies For The Treatment Of Limb-Girdle Muscular Dystrophies 4/14/2026

     Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced today a partnership with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies (LGMDs).

  7. Ensorcell Launches Versaweld™ Precision Tube Welding Platform At INTERPHEX 2026 4/10/2026
  8. Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 With Selection Of Cytovance Biologics For Cgmp Manufacturing 4/10/2026
  9. Symbiosis Expands Commercial Capabilities With Addition Of New Stability Chamber 4/1/2026

    Symbiosis Pharmaceutical Services (Symbiosis), a Contract Development and Manufacturing Organisation (CDMO) specialising in the sterile GMP manufacturer of injectable drug products, has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber.

  10. Samsung Biologics Completes Acquisition Of GSK's Manufacturing Facility In Rockville, Maryland 3/31/2026

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.